Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02424435 · ClinicalTrials.gov registry record · Early Phase 1
Methylprednisolone Treatment of Friedreich Ataxia
A Early Phase 1 study, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
NCT02424435 is a Early Phase 1 study that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 11 participants.
The verdict
NCT02424435, a Early Phase 1 study, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study will explore whether methylprednisolone treatment is safe, well-tolerated, and beneficial in patients that are diagnosed with Friedreich Ataxia (FRDA). The study will also explore if methylprednisolone has any effects on biomarkers associated with FRDA. All subjects in the study will receive the same steroid treatment.
Interventions
- DRUG Methylprednisolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-06 |
| Est. Completion | 2018-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02424435
The ClinicalTrials.gov registry entry for NCT02424435 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Methylprednisolone is the first listed.
NCT02424435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02424435 about?
NCT02424435 is a clinical study titled "Methylprednisolone Treatment of Friedreich Ataxia". This study will explore whether methylprednisolone treatment is safe, well-tolerated, and beneficial in patients that are diagnosed with Friedreich Ataxia (FRDA). The study will also explore if methylprednisolone has any effects on biomarkers associated with FRDA. All subjects in the study will rece...
What is the current status of trial NCT02424435?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2015-06. Estimated completion is 2018-04.
What interventions are being tested in trial NCT02424435?
The interventions under investigation include: Methylprednisolone (DRUG).
Who is sponsoring clinical trial NCT02424435?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.